Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4403796 | 0.75 | RAB9A (0.56) | L3MBTL1TSHRRAB9A | |
| SCHEMBL26717815 | 0.74 | TRPV1 (0.56) | L3MBTL1TSHRRAB9A | |
| SCHEMBL4404394 | 0.74 | TRPV1 (0.56) | L3MBTL1TSHRRAB9A | |
| SCHEMBL4411938 | 0.73 | RAB9A (0.57) | L3MBTL1TSHRRAB9ANR1H3 | |
| SCHEMBL4414653 | 0.71 | SMN1; SMN2 (0.53) | SMN1; SMN2POLBL3MBTL1TSHRMAPK1 | |
| SCHEMBL4411343 | 0.71 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBL3MBTL1TSHRMAPK1 | |
| Propionic Acid SCHEMBL10593320 | 0.71 | POLB (0.64) | SMN1; SMN2POLBL3MBTL1TSHRMAPK1 | |
| SCHEMBL4617609 | 0.70 | SMN1; SMN2 (0.56) | SMN1; SMN2POLBL3MBTL1TSHRMAPK1 | |
| SCHEMBL4405908 | 0.69 | RAB9A (0.61) | SMN1; SMN2L3MBTL1TSHRRAB9AHPGD | |
| SCHEMBL4638378 | 0.69 | SMN1; SMN2 (0.51) | SMN1; SMN2POLBL3MBTL1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041832-B2 | Processes for preparing losartan and losartan potassium | TAVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-05-09 | — | — | US | claimed |
| EP-1474417-B1 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMA (IL) | 2006-03-22 | — | — | EP | claimed |
| EP-1474417-A2 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-10 | — | — | EP | claimed |
| US-20040034077-A1 | Processes for preparing losartan and losartan an potassium | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2004-02-19 | — | — | US | claimed |
| WO-2003093262-A2 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-13 | — | — | WO | claimed |
| US-7041832-B2 | Processes for preparing losartan and losartan potassium | TAVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-05-09 | — | — | US | disclosed |
| EP-1474417-B1 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMA (IL) | 2006-03-22 | — | — | EP | disclosed |
| EP-1634880-A2 | Processes for preparing losartan and losartan potassium | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-03-15 | — | — | EP | disclosed |
| EP-1474417-A2 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-10 | — | — | EP | disclosed |
| US-20040034077-A1 | Processes for preparing losartan and losartan an potassium | TEVA PHARMACEUTICALS INDUSTRIES, LTD. (IL) | 2004-02-19 | — | — | US | disclosed |
| WO-2003093262-A2 | PROCESSES FOR PREPARING LOSARTAN AND LOSARTAN POTASSIUM | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034077-A1 | Processes for preparing losartan and losartan an potassium | REN, ACE, AGT | SMN1; SMN2 4057/4885POLB 2799/4885L3MBTL1 1182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.